Background: A large dosage pediatric formulation of amoxicillin/ clavulanate with an improved pharmacokinetic/pharmacodynamic profile was developed to eradicate many penicillin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae (including ␤-lactamase-producing strains). Methods: This randomized, investigator-blinded, multicenter trial examined treatment of bacterial acute otitis media (AOM) in children 6 -30 months of age with amoxicillin/clavulanate (90/6.4 mg/ kg/d in 2 divided doses for 10 days) versus azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days). Tympanocentesis was performed at entry for bacteriologic assessment, at the on-therapy visit (day 4 -6) to determine bacterial eradication and at any time before the end-of-therapy visit (day 12-14) if the child was categorized as experiencing clinical failure. Clinical assessments were performed at the on-therapy, end-of-therapy and follow-up (day 21-25) visits. Results: We enrolled 730 children; AOM pathogens were isolated at baseline for 249 of the amoxicillin/clavulanate group and 245 of the azithromycin group. For children with AOM pathogens at baseline, clinical success rates at the end-of-therapy visit were 90.5% for amoxicillin/clavulanate versus 80.9% for azithromycin (P Ͻ 0.01), and those at the on-therapy and follow-up visits were 94.9% versus 88.0% and 80.3% versus 71.1%, respectively (all P Ͻ 0.05). At the on-therapy visit, pretherapy pathogens were eradicated for 94.2% of children receiving amoxicillin/clavulanate versus 70.3% of those receiving azithromycin (P Ͻ 0.001). Amoxicillin/clavulanate eradicated 96.0% of S. pneumoniae (92.0% of fully penicillin-resistant S. pneumoniae) and 89.7% of H. influenzae (85.7% ͓6 of 7 cases͔ of ␤-lactamase-positive H. influenzae). Corresponding rates for azithromycin were 80.4% (54.5%) for S. pneumoniae and 49.1% (100% ͓1 of 1 case͔) for H. influenzae (all P Ͻ 0.01 for betweendrug comparisons).
I
n recent years, an important factor affecting the management of acute otitis media (AOM) has been the increasing development of antimicrobial resistance among the common pathogens that cause AOM, particularly the worldwide prevalence of drug-resistant Streptococcus pneumoniae. In 1985, ϳ90% of S. pneumoniae strains isolated from patients with AOM were susceptible to penicillin (minimal inhibitory concentration ͓MIC͔ of Յ0.06 g/mL); by 1997, the susceptibility of S. pneumoniae to penicillin had decreased to 43%. 1 Of greater concern has been the appearance of S. pneumoniae isolates with resistance to multiple classes of antimicrobial agents, including macrolides. Among isolates of Haemophilus influenzae and Moraxella catarrhalis, ␤-lactamase production rates have increased from 16% and 88% of strains collected before 1985 to 44% and 96% of those collected in 1997, respectively. 1 A large dosage amoxicillin/clavulanate formulation (90/6.4 mg/kg/d; Augmentin ES-600; GlaxoSmithKline, Durham, NC) was approved in the United States for the treatment of children with recurrent and persistent cases of AOM, particularly those for whom S. pneumoniae with penicillin MICs of Յ2 g/mL or ␤-lactamase-positive H. influenzae or M. catarrhalis are suspected. [2] [3] [4] [5] Because this formulation and azithromycin are frequently prescribed for the treatment of children with this condition, we evaluated their bacteriologic and clinical efficacy in a randomized clinical trial designed to demonstrate statistically significant differences in efficacy between treatment groups in children 6 -30 months of age.
protocol was approved by national or local ethics committees or the institutional review board for each center. Informed consent was obtained from parents before study entry. Subjects. Children 6 -30 months of age were eligible for inclusion in the study if they had AOM, based on the presence of purulent otorrhea for Ͻ24 hours or middle ear effusion evidenced by at least 2 of the following tympanic membrane findings: (1) yellow or white discoloration, (2) opacification or (3) decreased or absent mobility measured with pneumatic otoscopy. Evidence of middle ear effusion needed to be accompanied by Ն1 of the following signs of inflammation: (1) ear pain (including unaccustomed tugging of the ear), (2) marked erythema or (3) distinct fullness or bulging of the tympanic membrane. 5 Children were excluded from the study for the following reasons: weight of Ͼ40 kg, otorrhea for Ͼ24 hours, presence of tympanostomy tubes or anatomic abnormalities associated with prolonged middle ear effusion, serious underlying disease, hypersensitivity to study medications or concomitant use of medications known to interact with the study drugs. We also excluded children who had received systemic antibiotic therapy within 72 hours, except when AOM developed while the patient was undergoing prophylactic antimicrobial therapy for AOM. Interventions and Assessments. We randomized (1:1) eligible children to receive either amoxicillin/clavulanate (90/6.4 mg/ kg/d in 2 divided doses for 10 days) or azithromycin (10 mg/kg for 1 day, followed by 5 mg/kg/d for 4 days), and we conducted baseline (day 1), on-therapy (day 4 -6), end-of-therapy (day [12] [13] [14] and follow-up (day 21-25) clinical assessments. Efficacy assessments were conducted for children with bacterial AOM. For bacteriologic assessments, we performed tympanocentesis for all children with an intact tympanic membrane at the initial visit. For children with otorrhea for Ͻ24 hours, direct sampling of otorrhea or tympanocentesis was performed. We considered S. pneumoniae, H. influenzae, M. catarrhalis and Streptococcus pyogenes AOM pathogens. A second sample of middle ear fluid was obtained at the on-therapy visit from children who (1) had S. pneumoniae at baseline, (2) or had AOM pathogen(s) at baseline and either experienced clinical failure or withdrew from the study before the end of therapy. Exceptions included a center in Israel, where repeat tympanocentesis was performed at the on-therapy visit for all children with AOM pathogens at baseline, and a center in the United States, where on-therapy tympanocentesis was performed only for children with nonpenicillin-susceptible S. pneumoniae (MIC Ն 0.12 g/mL) at baseline. Outcomes. Compliance was assessed on the basis of medication diaries completed by the parents and comparisons of the amount of medication dispensed with that returned. Clinical response at the end of therapy (day 12-14) among children with bacterial AOM represented the primary efficacy endpoint for the study. Children were classified as experiencing clinical success if they had lessening or complete resolution of otoscopic signs of acute infection and symptoms of inflammation, with or without middle ear effusion, such that no additional antibiotic therapy was needed for AOM. Children were assigned a clinical response of failure if there was an inability to resolve or improve the otoscopic signs of acute infection and symptoms of inflammation after Ն72 hours of therapy, such that additional antibiotic therapy was prescribed for AOM, or if a valid assessment of the clinical outcome could not be made. This group included children who did not return for assessment at this visit. Similar criteria were used for the on-therapy visit. At the follow-up visit, children were classified as experiencing clinical success if they demonstrated a persistent clinical cure and as experiencing clinical failure if they had a recurrence of AOM that required additional antibiotic therapy. This category of clinical failure also included children categorized as experiencing clinical failure at the on-therapy or end-of-therapy visits and those who did not return for the assessment.
Bacteriologic response at the on-therapy and end-oftherapy visits was defined as success if there was eradication of the initial AOM pathogen (with or without the presence of a new pathogen), as demonstrated with repeat tympanocentesis, or a lack of middle ear fluid, as determined through either observation or tympanocentesis. Children were classified as experiencing bacteriologic failure if the initial pathogen persisted in the middle ear fluid at the on-therapy visit or before the end-of-therapy visit. Bacterial Isolation and Susceptibility Testing. Pathogens recovered from middle ear fluid at local laboratories were sent to a central laboratory for confirmation of identification and susceptibility testing. Determination of the penicillin, amoxicillin, amoxicillin/clavulanate, erythromycin and azithromycin MICs for the 4 protocol-defined AOM pathogens was performed with broth microdilution methods, according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines 6 and guidelines of the plate manufacturer (Trek Diagnostics, Cleveland, OH). MIC results were interpreted according to NCCLS guidelines, 7 and isolates were classified as susceptible, intermediate or resistant to each drug. Because no NCCLS breakpoints for amoxicillin/ clavulanate (90/6.4 mg/kg/d) have been assigned, the breakpoint for conventional formulations was used. Isolates of H. influenzae and M. catarrhalis were tested for ␤-lactamase production with Cefinase disks (Becton Dickinson, Sparks, MD), according to the manufacturer's instructions. Statistical Analyses. We assumed overall clinical success rates at the end of therapy of 86% for patients treated with amoxicillin/clavulanate and 75% for patients treated with azithromycin. 8 Accordingly, a total of 203 children per treatment arm were required to detect a difference with 80% power at a significance level of 0.05. With the assumptions that ϳ70% of all middle ear fluid sample cultures would yield a pathogen and 80% of children who had a pathogen would qualify for the per-protocol population, 203/(0.7 ϫ 0.8) resulted in 363 children required per treatment arm. The treatment difference and 95% confidence intervals (CIs) were determined for the difference between treatment groups at each endpoint. Fisher's exact test or continuity-corrected 2 test P values were calculated as appropriate.
RESULTS

Subjects.
We randomized 731 children to amoxicillin/clavulanate (368 children) or azithromycin (363 children). One child in the amoxicillin/clavulanate group did not receive study medication; therefore, 730 children were included in the safety analysis. The flow of children in the study is shown in Figure 1 . The 2 treatment groups were well matched with respect to demographic characteristics and risk factors for AOM (Table 1) . In general, children in both treatment groups were relatively young (mean age, 15.1 and 15.2 months for the amoxicillin/ clavulanate and azithromycin groups, respectively); 87.6% of children were Յ24 months of age. Approximately two-thirds of the children had siblings, one-third attended day-care centers, one-third had AOM and received systemic antimicrobial therapy in the 30 days before enrollment and one-third were exposed to tobacco smoke pollution at home. Bacteriologic Efficacy. Determination of bacteriologic responses was limited to children from whom pathogens were isolated at baseline and for whom the study protocols at the various study sites called for repeat tympanocentesis on day 4 -6. As described previously, repeat tympanocentesis was to be performed for children who in baseline tympanocentesis assessments had the following: (1) in Israel, any of the 4 AOM pathogens isolated; (2) at all other sites except Children's Hospital of Pittsburgh, any S. pneumoniae isolated; (3) at Children's Hospital of Pittsburgh, any nonsusceptible S. pneumoniae isolated. In addition, repeat tympanocentesis was performed at all sites in the event of clinical failure occurring before the end-of-therapy visit (day [12] [13] [14] . However, when repeat tympanocentesis was performed because of clinical failure, rather than because the child met the aforementioned criteria at the various sites, results were not included in bacteriologic efficacy analyses, to preclude bias that would result from the inclusion only of children who experienced clinical failure (see below). Therefore, given the particular design of this study, S. pneumoniae was the pathogen for which bacteriologic results were most frequently available. Bacteriologic response at the on-therapy and end-of-therapy visits was defined as success if there was eradication of the initial AOM pathogen (with or without the presence of a new pathogen), as demonstrated with repeat tympanocentesis, or the absence of middle ear fluid in otoscopic examinations.
Children were classified as experiencing bacteriologic failure if the initial pathogen persisted in the middle ear fluid at the on-therapy visit or before the end-of-therapy visit. Among the 183 children categorized as experiencing bacteriologic success at day 4 -6, 24.8% (25 of 101 children) in the amoxicillin/clavulanate group and 25.6% (21 of 82 children) in the azithromycin group were so categorized because of the absence of middle ear effusion, whereas 75.2% (76 of 101 children) in the amoxicillin/clavulanate group and 74.4% (61 of 82 children) in the azithromycin group were so categorized on the basis of bacteriologic findings for middle ear fluid specimens. Among the children for whom bacteriologic responses were determined, amoxicillin/clavulanate, compared with azithromycin, demonstrated significantly higher rates of eradication of AOM pathogens (101 of (Table 4) . For children with H. influenzae isolated at baseline, marked differences between treatment groups, favoring amoxicillin/clavulanate, were apparent in clinical success rates at the end-of-therapy visit (day 12-14) ( Table 5) . A trend for greater clinical efficacy with amoxicillin/clavulanate among children with PRSP and azithromycin-resistant S. pneumoniae strains was noted, although differences between treatment groups did not reach statistical significance (Table  5) . When all children with bacterial AOM were included, differences between treatment groups did not reach statistical significance (Table 4) . Among children for whom no AOM pathogens were isolated at baseline, clinical success rates did not differ significantly between the 2 treatment groups, either at the end-of-therapy visit on day 12-14 (81.4% ͓96 of 118 children͔ in both groups) or at the follow-up visit on day 21-25 (68.6% ͓81 of 118 children͔ in the amoxicillin/clavulanate group versus 76.3% ͓90 of 118 children͔ in the azithromycin group).
Relationship Between Bacterial Eradication at the OnTherapy Visit and Clinical
Outcomes at the End-ofTherapy Visit. Among children from whom S. pneumoniae and/or H. influenzae were recovered at baseline and who experienced bacteriologic failure at the on-therapy visit (ie, cultures remained positive), clinical failure at the end-oftherapy visit occurred for 5 of 7 children (71.4%) treated with amoxicillin/clavulanate and 20 of 49 children (40.8%) treated with azithromycin. Bacteriologic success at the on-therapy visit was associated with clinical success at the end-oftherapy visit for 96 of 105 children (91.4%) treated with amoxicillin/clavulanate and 80 of 89 children (89.9%) treated with azithromycin. These relationships were similar for children from whom PRSP was recovered at baseline. Therefore, clinical failure at the end-of-therapy visit and bacteriologic failure at the on-therapy visit occurred for 1 of 2 children (50%) treated with amoxicillin/clavulanate and 5 of 12 children (42%) treated with azithromycin; clinical success at the end-of-therapy visit and bacteriologic success at the ontherapy visit occurred for 20 of 22 children (90.9%) treated with amoxicillin/clavulanate and 10 of 10 children (100%) treated with azithromycin. Treatment Compliance. Rates of compliance with study medications were high in both treatment groups (amoxicillin/ clavulanate, 85.8%; azithromycin, 91.3%). Clinical success rates at the end of therapy for children who were noncompliant with study medication were 38.5% (20 of 52 children) Eradication  2  100  1  100  Total  2  100  1  100 *Two children in the amoxicillin/clavulanate group and 9 children in the azithromycin group did not undergo repeat tympanocentesis.
Moraxella catarrhalis
A/C indicates amoxicillin/clavulanate; AZI, azithromycin.
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and 40.6% (13 of 32 children) for children randomized to amoxicillin/clavulanate and azithromycin, respectively. Safety. Adverse events and withdrawals from the study according to treatment group are shown in Table 6 .
DISCUSSION
Among children with AOM, an antimicrobial agent with relatively low antibacterial efficacy may result in similar clinical outcomes, compared with those that result from using an antimicrobial agent with high antibacterial efficacy. 9, 10 However, rates of bacterial eradication are helpful in discriminating among agents. Accordingly, there is a growing acceptance of the need to take pharmacokinetic/pharmacodynamic measures into consideration when choosing antimicrobial therapy for children with AOM. The best predictors of efficacy are the time during which an antimicrobial agent maintains serum concentrations above the MIC of the pathogen for ␤-lactam antimicrobial agents and the ratio of the area under the concentration-time curve to the MIC for macrolide/azalide antimicrobial agents. [11] [12] [13] For amoxicillin, a serum concentration greater than the MIC for 40 -50% of the dosing interval is predictive of 80 -85% bacterial eradication in AOM.
11 Amoxicillin/clavulanate (90 and 6.4 mg/kg/d of the amoxicillin and clavulanate components, respectively) was developed to sustain amoxicillin/clavulanate concentrations in middle ear fluid at levels that would predict eradication of PRSP with amoxicillin/clavulanate MICs of Յ4 g/mL. Applying the area under the concentration-time curve/MIC model, the prediction for azithromycin, at the dosage used in this study, would be that macrolide-resistant S. pneumoniae strains and most H. influenzae strains would not be eradicated at a rate higher than that observed without antibiotics.
Previous studies among children with AOM showed a clear relationship between early (day 4 -5) eradication of infecting pathogens from the middle ear fluid and positive clinical outcomes. 14, 15 The results of the current study are consistent with previous reports. There was a strong correlation between early bacteriologic success at the on-therapy visit (day 4 -6) and clinical success at the end-of-therapy visit (day [12] [13] [14] in the combined treatment groups for both S. 20 Therefore, despite the in vitro findings that most H. influenzae strains are susceptible to azithromycin (according to the NCCLS definition of having a MIC of Ͻ8 g/mL), the results of clinical studies with bacteriologic outcomes demonstrate that almost all H. influenzae isolates are, in fact, resistant to azithromycin, at least with the concentrations and dynamics achieved with the currently recommended dosages.
Children Ͻ2 years of age are more likely than older children to have AOM caused by resistant pathogens, such as PRSP, and accordingly are more likely to experience clinical failure. 14, 15, [21] [22] [23] The overall prevalence of PRSP (26.6% of all S. pneumoniae isolates) in the present study, in which 86% of children were Ͻ2 years of age, is consistent with these observations. Despite a relatively high prevalence of PRSP, amoxicillin/clavulanate eradicated S. pneumoniae in most instances (bacteriologic success rate of 96%). More than one-half of the PRSP isolates were also resistant to macrolides. This level of penicillin-macrolide cross-resistance is similar to that reported previously in a surveillance study of Western Europe and the United States between 1998 and 2000. 24 In contrast to the high PRSP eradication rates achieved with amoxicillin/clavulanate (92.0%), azithromycin eradicated 54.5% of PRSP isolates (P Ͻ 0.05).
A recent report by Arrieta et al 25 compared a larger dosage of azithromycin (20 mg/kg/d administered once daily for 3 days) with amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses daily). The authors concluded that azithromycin resulted in improved clinical outcomes at day 28 -32 and that clinical efficacies for the 2 antimicrobial agents were comparable for microbiologically evaluable children. There were substantial differences in study design between the study by Arrieta et al 25 and the current study. Methodologic limitations of the study by Arrieta et al 25 included (1) a sample size too small for a single-tympanocentesis study design; (2) a low rate of bacterial AOM at baseline (55%); (3) fewer children (ϳ65%) Ͻ24 months of age, ie, those most likely to experience treatment failure; 15 (4) use of day 28 -32 visit results as the primary outcome; and (5) performance of repeat tympanocentesis for only 7 of 64 children categorized as experiencing clinical failure (mostly at one study site). Despite these limitations and differences in study design, outcomes for children with AOM caused by H. influenzae (azithromycin, 67%; amoxicillin/clavulanate, 81%; 95% CI of the difference, Ϫ34.7% to Ϫ6.8%) were similar to those reported previously 8 and to those in our study. We conclude that amoxicillin/clavulanate was effective in eradicating AOM pathogens and that this led to high clinical cure rates. Amoxicillin/clavulanate was significantly more effective than azithromycin bacteriologically and clinically. The relatively high bacteriologic and clinical efficacy of amoxicillin/clavulanate, together with its excellent safety profile, makes it a preferred antimicrobial choice for the treatment of children with recurrent or persistent AOM, particularly those at risk for infection with nonsusceptible S. pneumoniae and/or ␤-lactamase-positive H. influenzae or M. catarrhalis.
